AcelRx Pharmaceuticals’ programs to feature at upcoming annual meeting

NewsGuard 100/100 Score
Oct 15 2009

AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 1 studies evaluating the pharmacokinetics of its oral transmucosal NanoTab(TM) formulation of sufentanil will be featured in two oral presentations at the upcoming American Society of Anesthesiologists Annual Meeting in New Orleans.

Dr. Pamela Palmer, Chief Medical Officer of AcelRx, will present in the following sessions. Abstracts are available through the American Society of Anesthesiologists web site.

Tuesday, October 20, 2009 Oral Session - Chronic & Cancer Pain 8:00 am, Room 355 Abstract 1040 "Pharmacokinetics and Dose Proportionality of Sublingual Sufentanil NanoTab in Healthy Volunteers" Tuesday, October 20, 2009 Oral Session - Regional Anesthesia & Acute Pain 1:00 pm, Room 355 Abstract 1222 "Single- and Repeat-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab in Healthy Volunteers"

Source:

AcelRx Pharmaceuticals, Inc.

Posted in: Pharmaceutical News

Tags: , , , , ,

Comments (0)

Suggested Reading

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Study highlights global fertility decline and its implications for the future
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Lancet Commission predicts sharp increase in global prostate cancer cases
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
Supply chain assessment and management, optimizing pharmaceutical supply chains
New urine-based test improves identification of high-grade prostate cancer
LabVantage celebrates customer success with record number of software deployments in FY 2024

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk